Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Must have recovered from all side effects of their most recent systemic or local treatment
Adequate hematological, renal and liver function
For solid tumors only:
Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer) with a BRAF V600 mutation and that are resistant to standard therapy or for which standard or curative therapy does not exist
Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)
For multiple myeloma only:
Confirmed diagnosis of multiple myeloma with a BRAF V600 mutation
Must have received at least one prior systemic therapy for the treatment of multiple myeloma
Treated with local radiotherapy
Must have relapsed and/or refractory multiple myeloma with measurable disease
You may not be if
Melanoma, papillary thyroid cancer or hematological malignancies (with the exception of multiple myeloma)
Uncontrolled concurrent malignancy
Multiple myeloma: solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia
Active or untreated central nervous system (CNS) metastases
History of or known carcinomatous meningitis
Concurrent administration of any anti-cancer therapies other than those administered in this study
Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that would, in the investigator's opinion, contraindicate participation in this study
Clareo Health | A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
